Key Dates

Related Announcements

• November 19, 2024 - NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional). See NOFO RFA-HL-26-014.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The National Heart, Lung, and Blood Institute (NHLBI) is announcing a correction to RFA-HL-26-014 NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional). Changes are shown in bold italics below. 

Currently reads in RFA-HL-26-014:

Section II. Award Information

Application Types Allowed

Resubmission (All Phases) - (Phase IIB previously submitted under this NOFO or RFA-HL-19-017).
 

Modified to read in RFA-HL-26-014 (changes shown in bold italics):

Application Types Allowed

Resubmission (All Phases) - (Phase IIB previously submitted under this NOFO or RFA-HL-23-009)

All other aspects of RFA-HL-26-014 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Stephanie Davis, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 1-301-496-8412
Email: [email protected]